|
PureTech Health PLC - Boston, Massachusetts-based biotech and pharmaceutical firm - Promotes interim Chief Executive Officer Robert Lyne to CEO on a permanent basis from Thursday. Lyne has served as interim CEO since July, having joined the company in January 2024 as chief portfolio officer. He has overseen progress across PureTech’s programmes and advancing strategic and operational priorities. Lyne was previously CEO of Arix Bioscience PLC. Current stock price: 121.96 pence, up 1.1% on Thursday morning in London 12-month change: down 26% Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
